Stocktoria
Glucotrack, Inc. GCTK
Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2013-04-09
Glucotrack, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $208,000 | $17.0B | $589,462 | $611,689 |
| R&D expense | $9.8M | $9.5M | $4.7M | $2.0M | $1.8M | $1.5M | $1.6M | $3.0M | $3.2M | $2.9M |
| SG&A expense | — | — | — | — | $139,000 | $415,000 | — | — | $1.5M | $1.1M |
| Operating income | -$16.1M | -$14.5M | -$7.1M | -$4.4M | -$4.0M | -$3.1M | $3.5M | -$6.5M | $10.6M | -$5.7M |
| Interest expense | — | $44,000 | — | — | — | — | — | — | — | — |
| Net income | -$19.4M | -$22.6M | -$7.1M | -$4.4M | -$4.1M | -$2.7M | $3.5M | -$6.7M | $10.3M | -$5.4M |
| EPS (diluted) | $31.22 | $4106.00 | $34.18 | $0.29 | $0.26 | $0.19 | $-0.02 | $-4.74 | $-1.87 | $-1.08 |
| Operating cash flow | -$15.2M | -$12.5M | -$6.6M | -$3.7M | -$3.8M | -$3.5M | -$3.9M | -$4.9M | -$5.9M | -$5.3M |
| Free cash flow | -$15.3M | -$12.6M | — | -$3.7M | -$3.8M | -$3.6M | -$3.9M | -$4.9M | -$5.9M | -$5.4M |
| Cash & equivalents | $7.4M | $5.6M | $4.5M | $2.3M | $6.1M | $9.8M | $419,000 | $97,079 | $53,782 | $148,836 |
| Inventory | — | — | — | — | — | $284,000 | $184,000 | $170,999 | $957,349 | $1.4M |
| Total assets | $7.8M | $5.9M | $4.9M | $2.4M | $6.3M | $10.6M | $1.1M | $688,186 | $1.7M | $2.5M |
| Total liabilities | $5.0M | $18.9M | $1.7M | $1.2M | $1.1M | $1.6M | $2.5M | $3.6M | $4.8M | $3.4M |
| Shareholders' equity | $2.8M | -$13.0M | $3.2M | $1.2M | $5.2M | $9.0M | -$1.4M | -$2.9M | -$16.6M | -$10.9M |
Growth · year-over-year · Revenue CAGR -30.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | — | — | -100.0% | +2883885.7% | -3.6% | +327.3% |
| Net income growth | — | — | — | — | — | -176.7% | — | -165.0% | — | — |
| EPS growth | -99.2% | +11912.9% | +11686.2% | +11.5% | +36.8% | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.